Patents by Inventor Yuli Xie

Yuli Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20180305314
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 25, 2018
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Potent non-urea inhibitors of soluble epoxide hydrolase
    Patent number: 10005732
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: June 26, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • GLUCOSE METABOLISM MODULATING COMPOUNDS
    Publication number: 20160311773
    Abstract: The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyperglycemia.
    Type: Application
    Filed: April 20, 2015
    Publication date: October 27, 2016
    Inventors: Paul Harris, Antonella Maffei, Yuli Xie, Donald Landry
  • Neuronal pain pathway modulators
    Patent number: 9402826
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: August 2, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20160052883
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: November 2, 2015
    Publication date: February 25, 2016
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Hypoglycemic dihydropyridones
    Patent number: 9260391
    Abstract: The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: February 16, 2016
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yuli Xie, Shixian Deng, Donald W. Landry, Paul Harris, Antonella Maffei
  • Potent non-urea inhibitors of soluble epdxide hydrolase
    Patent number: 9175285
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: November 3, 2015
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Lu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • NEURONAL PAIN PATHWAY MODULATORS
    Publication number: 20150126576
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Application
    Filed: September 29, 2014
    Publication date: May 7, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • METHODS OF DIAGNOSING, PREVENTING, AND TREATING BONE MASS DISEASES
    Publication number: 20150111908
    Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
    Type: Application
    Filed: May 20, 2014
    Publication date: April 23, 2015
    Inventors: Gerard Karsenty, Patricia F. Ducy, Yuli Xie, Donald Landry, Vijay Yadav
  • Glucose metabolism modulating compounds
    Patent number: 9012471
    Abstract: The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyper-glycemia.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: April 21, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Paul Harris, Antonella Maffei, Yuli Xie, Donald Landry
  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20140349368
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: February 17, 2014
    Publication date: November 27, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Lu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Neuronal pain pathway modulators
    Patent number: 8846742
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: September 30, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY
    Publication number: 20140275165
    Abstract: The present invention relates to compounds with activity as BACE1 and NF?B modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 18, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Tae-Wan Kim, Shi-Xian Deng, Gangli Gong, Jeremy C. Hwang, Yuli Xie, Yidong Liu, Kirsten Alison Rinderspacher
  • Methods of treating bone mass diseases
    Patent number: 8759364
    Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: June 24, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Gerard Karsenty, Patricia F. Ducy, Yuli Xie, Donald Landry, Vijay Kumar Yadav
  • Compounds that inhibit NF?B and BACE1 activity
    Patent number: 8685963
    Abstract: The present invention relates to compounds with activity as BACE1 and NF?B modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 1, 2014
    Assignee: The Trustees of Columbia University in the city of New York
    Inventors: Donald W. Landry, Shi Xian Deng, Gangli Gong, Yuli Xie, Yidong Liu, K. Alison Rinderspacher
  • Potent non-urea inhibitors of soluble epoxide hydrolase
    Patent number: 8653273
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: February 18, 2014
    Assignee: The Trustees of Columbia University in the city of New York
    Inventors: Kirsten Alison Rinderspacher, Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng
  • COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY
    Publication number: 20120064099
    Abstract: The present invention relates to compounds with activity as BACE1 and NF?B modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
    Type: Application
    Filed: April 26, 2011
    Publication date: March 15, 2012
    Applicant: The Trustees of Columbia University in The City of New York
    Inventors: Donald W. Landry, Tae-Wan Kim, Shi Xian Deng, Gangli Gong, Jeremy C. Hwang, Yuli Xie, Yidong Liu, K. Alison Rinderspacher
  • Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase
    Publication number: 20120029022
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: July 7, 2011
    Publication date: February 2, 2012
    Applicant: The Trustees Of Columbia Univesity In The City Of New York
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • HYPOGLYCEMIC DIHYDROPYRIDONES
    Publication number: 20110294800
    Abstract: The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 1, 2011
    Applicant: The Trustees Of Columbia University in the City of New York
    Inventors: Yuli Xie, Shixian Deng, Donald W. Landry, Paul Harris, Antonella Maffei
  • METHODS OF DIAGNOSING, PREVENTING AND TREATING BONE MASS DISEASES
    Publication number: 20110152220
    Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
    Type: Application
    Filed: March 30, 2009
    Publication date: June 23, 2011
    Inventors: Gerard Karsenty, Patricia F. Ducy, Yuli Xie, Donald Landry, Vijay Kumar Yadav